Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of JW0102 vs JW0101 + C2101 in Healthy Volunteers
NCT06355349Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pitavastatin, valsartan and amlodipine in dyslipidemia and hypertension (HTN) (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration and Maximum Plasma Concentration. Started Apr 2023; status: completed.
02
Drugs
pitavastatinvalsartanamlodipine
03
Conditions
dyslipidemiahypertension (HTN)
Beyond the preview
Go deeper on NCT06355349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355349.